Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Cu-AKY-1189

Radiopharmaceutical · developed by Aktis Oncology

Phase 1 Most advanced trial

AKTS Developer

1 Registered trials

What is Cu-AKY-1189?

Cu-AKY-1189 is a copper-64 labeled imaging agent (64Cu-AKY-1189) studied in patients with urothelial, breast, lung, cervical, colorectal and head and neck cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Radiopharmaceutical
Therapy area: Oncology
Developer: Aktis Oncology, Inc. (AKTS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07020117	Phase 1	Urothelial Carcinoma Bladder	Recruiting	AKTS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical AdenocarcinomaColorectal AdenocarcinomaHead and Neck CancerHormone Receptor Positive Breast AdenocarcinomaNon Small Cell Lung CancerTriple Negative Breast Cancer (TNBC)Urothelial Carcinoma Bladder

More from Aktis Oncology

Ac-AKY-1189 Phase 1 Ac-AKY-2519 Phase 1 Cu-AKY-2519 Phase 1

Sources

ClinicalTrials.gov NCT07020117

Updated Oct 11, 2026. Something wrong or missing? Report it on the AKTS page.

Follow AKTS, the company behind Cu-AKY-1189

See AKTS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AKTS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z